This open-label, prospective, single-arm, multicenter study will evaluate the relationship of
the markers of inflammation and progression-free survival (PFS) in participants with
previously untreated metastatic colorectal cancer. The study consists of two phases: Phase A
treatment: oral capecitabine plus infusional oxaliplatin (XELOX) plus bevacizumab, or
modified infusional 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (mFOLFOX6) plus
bevacizmab administered until first disease progression. Participants will then continue with
Phase B treatment: infusional 5-FU, LV and irinotecan (FOLFIRI) plus bevacizumab until second
disease progression. The anticipated time on study treatment is 4 years.